Iovance Biotherapeutics Announces The Appointment Of Corleen Roche As Chief Financial Officer

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced the appointment of Corleen Roche as its new Chief Financial Officer, effective August 6, 2025.

Corleen Roche brings with her over 30 years of experience in the biotechnology and life sciences sector, having held senior financial leadership positions across several prominent public companies. Most recently, she served as the CFO of CG Oncology, a late-stage clinical biopharmaceutical company. Prior to that, she held key financial roles including Chief Financial Officer of Immunome, U.S. CFO at Biogen, North America CFO at CSL Behring, and senior finance positions at Sandoz, Wyeth, and Pfizer.

Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer, President and General Counsel, said in a statement, “I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch. Corleen’s experience in executive financial leadership roles and multiple product launches will be invaluable as we focus on growing revenue, managing our balance sheet and advancing our mission of developing and delivering novel therapies to patients with solid tumors.”

Ms. Roche mentioned, “I am excited to join Iovance to navigate our continued revenue growth and focus our pipeline investments on the highest value opportunities. I am committed to the company’s patient-focused mission while achieving our financial goals to build a profitable biotechnology company.”

Throughout her career, Ms. Roche has played a significant role in shaping financial strategies to support major product launches. Notably, she was involved in the commercial readiness for ZARXIO®, the first biosimilar approved in the United States; GLATOPA™, the first complex generic drug for multiple sclerosis; and PREVNAR 13®, a widely used pneumococcal conjugate vaccine. Her experience spans financial planning, budgeting, investor relations, and managing commercial transitions in the healthcare sector.

Ms. Roche holds a Bachelor of Arts degree in accountancy from Villanova University and brings a deep understanding of both financial operations and strategic planning in biotech environments. Her appointment is expected to support Iovance’s continued growth and advancement of its TIL therapies.